Patents by Inventor Andreas Bergmann

Andreas Bergmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10340884
    Abstract: In an arrangement having a DMS filter, it is provided to symmetrically divide at least one of the transducers (W) of the DMS filter (DMS) into two sub-transducers (T,T?) electrically connected in parallel and to shift them apart from each other by an amount of at least a half wavelength. This results in the signals of the two sub-transducers canceling each other out at a frequency in a stopband and thereby generating an attenuation pole in the upper blocking region.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: July 2, 2019
    Assignee: SnapTrack, Inc.
    Inventor: Andreas Bergmann
  • Publication number: 20190145981
    Abstract: The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.
    Type: Application
    Filed: April 20, 2017
    Publication date: May 16, 2019
    Applicant: SPHINGOTEC THERAPEUTICS GMBH
    Inventor: Andreas BERGMANN
  • Patent number: 10254289
    Abstract: The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 9, 2019
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
  • Publication number: 20190092857
    Abstract: Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.
    Type: Application
    Filed: December 10, 2018
    Publication date: March 28, 2019
    Applicant: ADRENOMED AG
    Inventor: Andreas BERGMANN
  • Patent number: 10227405
    Abstract: Patients having a chronic or acute disease or acute condition, especially patients at the ICU (Intensive Care Unit) suffer from fluid imbalance. The present invention provides a medicament for regulating the fluid balance and/or improving the fluid balance of such patients. Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease or acute condition. The present invention also provides a method for regulating the fluid balance in a patient having a chronic or acute disease or acute condition. Subject matter of the present invention is an anti-Adrenomedullin ADM antibody or anti-ADM non-Ig scaffold or an anti-adrenomedullin antibody fragment for use in therapy of a chronic or acute disease or acute condition of a patient for the regulation of fluid balance.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: March 12, 2019
    Assignee: ADRENOMED AG
    Inventor: Andreas Bergmann
  • Patent number: 10221238
    Abstract: Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 5, 2019
    Assignee: ADRENOMED AG
    Inventor: Andreas Bergmann
  • Publication number: 20190049470
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 14, 2019
    Applicant: SPHINGOTEC GMBH
    Inventor: Andreas BERGMANN
  • Publication number: 20190010226
    Abstract: Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 10, 2019
    Applicant: ADRENOMED AG
    Inventor: Andreas Bergmann
  • Patent number: 10114029
    Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 30, 2018
    Assignee: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • Patent number: 10077192
    Abstract: Production of highly pure comminuted polycrystalline silicon from polycrystalline silicon rods produced by the Siemens process is facilitated by removal of graphite residues from the electrode ends of the rods by removing the contaminated end portions by means of mechanical impulses.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 18, 2018
    Assignee: WACKER CHEMIE AG
    Inventors: Stefan Faerber, Andreas Bergmann, Reiner Pech, Siegfried Riess
  • Patent number: 10067063
    Abstract: The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: September 4, 2018
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Nils Morgenthaler
  • Publication number: 20180246127
    Abstract: Subject matter of the present invention is a method for determining the fat processing activity and/or predicting the risk of obesity in a subject comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with fat processing activity and/or the risk of incidence of obesity in said subject, wherein an elevated level is indicative of enhanced fat processing activity and/or predictive for an enhanced risk of getting obesity.
    Type: Application
    Filed: February 26, 2016
    Publication date: August 30, 2018
    Applicant: SPHINGOTEC GMBH
    Inventors: Andreas BERGMANN, Olle MELANDER
  • Publication number: 20180194769
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
  • Publication number: 20180194760
    Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 12, 2018
    Inventors: Martin R. JEFSON, John A. LOWE, III, Fabian DEY, Andreas BERGMANN, Andreas SCHOOP
  • Publication number: 20180185882
    Abstract: Polysilicon chunks or granules are classified into size fractions using a mechanical screen having a profiled surface having peaks and valleys, and terminating in widening slots through which a polysilicon size fraction falls. The device is effective and the slots are resistant to clogging.
    Type: Application
    Filed: March 15, 2016
    Publication date: July 5, 2018
    Applicants: SILTRONIC AG, WACKER CHEMIE AG
    Inventors: Andreas BERGMANN, Thomas BUSCHHARDT, Simon EHRENSCHWENDTNER, Christian FRAUNHOFER
  • Publication number: 20180143190
    Abstract: Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proAM; SEQ ID NO:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proAM.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: B.R.A.H.M.S GmbH
    Inventors: Andreas BERGMANN, Joachim STRUCK
  • Publication number: 20180128838
    Abstract: The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (CKD) using Pro-Enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases. Subject matter of the invention is also a method of predicting the worsening or improvement of kidney function or dysfunction in healthy and diseased individuals.
    Type: Application
    Filed: April 21, 2016
    Publication date: May 10, 2018
    Applicant: sphingotec GmbH
    Inventors: Andreas BERGMANN, Olle MELANDER
  • Publication number: 20180123564
    Abstract: In a resonator, two interdigital transducers (W1,W2) are electrically series-connected and arranged next to each other in the longitudinal direction within an acoustic track delimited by reflectors. Between the two interdigital transducers, a transition area (UEB) is formed in that the finger period p, which is defined as the distance between the finger centers of adjacent transducer fingers, is higher in comparison to the remaining interdigital transducer.
    Type: Application
    Filed: April 13, 2016
    Publication date: May 3, 2018
    Inventor: Andreas BERGMANN
  • Patent number: 9952229
    Abstract: Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopressin pro-hormone or fragments thereof in a sample of a subject.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: April 24, 2018
    Assignees: B.R.A.H.M.S. GmbH, The General Hospital Corporation
    Inventors: Joachim Struck, Andreas Bergmann, Olle Melander, Christopher Newton-Cheh, Thomas Wang
  • Publication number: 20180052179
    Abstract: A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Applicant: B.R.A.H.M.S GmbH
    Inventors: Andreas BERGMANN, Joachim STRUCK